High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Standard treatment for hepatitis C virus (HCV) using peginterferon and weight-based ribavirin often results in nonresponse.
• Investigating alternative dosing strategies for ribavirin is crucial for improving treatment outcomes in nonresponder patients.

Purpose of the Study:

• To evaluate the efficacy and safety of high-dose, concentration-monitored ribavirin in patients with previous nonresponse to standard therapy.
• To determine if individualized ribavirin dosing can achieve higher plasma concentrations and improve viral response.

Main Methods:

• Included patients with prior nonresponse to peginterferon and ribavirin.
• Dosed ribavirin to achieve plasma concentrations >15 μmol/L, with initial dosing based on renal function and body weight.
• Administered erythropoietin starting 2 weeks prior to antiviral therapy to mitigate anemia.

Main Results:

• Eighty percent of patients achieved an early viral response, with 60% HCV RNA negative by week 24.
• High-dose ribavirin significantly increased HCV RNA drop at week 12 (P < 0.001).
• Nine patients achieved undetectable HCV RNA by end of treatment; one had sustained viral response. Daily doses ranged from 1400-4400 mg.

Conclusions:

• Individualized high-dose ribavirin demonstrates a more pronounced early HCV RNA decline compared to standard dosing.
• The regimen is safe when coupled with close anemia monitoring and erythropoietin treatment.
• This approach offers a viable option for nonresponder patients, improving viral clearance rates.